Key facts
- Notable investors include Jolmo Investment, Guangdong Academy of Greater Bay Area Studies, Guangdong Collaborative Innovation Industry Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Ruifu Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Ruifu Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ruifu Pharmaceuticals
Manufacturer of small molecule pharmaceutical products designed to advance innovative drug development. The company offers proprietary drug research, clinical development programs, and commercialization capabilities across innovative therapeutic compounds, enabling healthcare institutions and pharmaceutical distributors to access clinically validated treatments and support the progression of novel therapies to market.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Ruifu Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ruifu Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ruifu Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.